Analysis Of Transfusion Dependence Development and Disease Evolution In Patients With MDS and Del(5q) and Without Transfusion Needs At Diagnosis

被引：0
|
作者：
Rojas, Silvia M.
Diez-Campelo, Maria
Luno, Elisa
Bernal, Teresa
Cabrero, Monica
Pedro, Carme
Calabuig, Marisa
Nomdedeu, Benet
Cedena, Teresa
Arrizabalaga, Beatriz
Garcia, Marta
Cervero, Carlos
Collado, Rosa
Azaceta, Gemma
Ardanaz, MarAa Teresa
Munoz, Juan A.
Xicoy, Blanca
Requena, Maria Jose
Bargay, Joan
Arilla, Maria Jesus
Amigo, Luz
Merchan, Brayan
Simiele, Adriana
Brunet, Salut
Gonzalez, Bernardo
Ramos, Fernando
Sole, Francesc
Consuelo, Del CaA'izo
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1542.1542
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1542
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Disease progression in del(5q) MDS patients treated with lenalidomide: analysis of risk factors and long-term outcome in 44 patients
    Giagounidis, A. A. N.
    Haase, S.
    Lohrbacher, V.
    Heinsch, M.
    Schuran, B.
    Aul, C.
    LEUKEMIA RESEARCH, 2007, 31 : S120 - S121
  • [32] Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion
    Toma, A.
    Kosmider, O.
    Chevret, S.
    Delaunay, J.
    Stamatoullas, A.
    Rose, C.
    Beyne-Rauzy, O.
    Banos, A.
    Guerci-Bresler, A.
    Wickenhauser, S.
    Caillot, D.
    Laribi, K.
    De Renzis, B.
    Bordessoule, D.
    Gardin, C.
    Slama, B.
    Sanhes, L.
    Gruson, B.
    Cony-Makhoul, P.
    Chouffi, B.
    Salanoubat, C.
    Benramdane, R.
    Legros, L.
    Wattel, E.
    Tertian, G.
    Bouabdallah, K.
    Guilhot, F.
    Taksin, A. L.
    Cheze, S.
    Maloum, K.
    Nimuboma, S.
    Soussain, C.
    Isnard, F.
    Gyan, E.
    Petit, R.
    Lejeune, J.
    Sardnal, V.
    Renneville, A.
    Preudhomme, C.
    Fontenay, M.
    Fenaux, P.
    Dreyfus, F.
    LEUKEMIA, 2016, 30 (04) : 897 - 905
  • [33] Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion
    A Toma
    O Kosmider
    S Chevret
    J Delaunay
    A Stamatoullas
    C Rose
    O Beyne-Rauzy
    A Banos
    A Guerci-Bresler
    S Wickenhauser
    D Caillot
    K Laribi
    B De Renzis
    D Bordessoule
    C Gardin
    B Slama
    L Sanhes
    B Gruson
    P Cony-Makhoul
    B Chouffi
    C Salanoubat
    R Benramdane
    L Legros
    E Wattel
    G Tertian
    K Bouabdallah
    F Guilhot
    A L Taksin
    S Cheze
    K Maloum
    S Nimuboma
    C Soussain
    F Isnard
    E Gyan
    R Petit
    J Lejeune
    V Sardnal
    A Renneville
    C Preudhomme
    M Fontenay
    P Fenaux
    F Dreyfus
    Leukemia, 2016, 30 : 897 - 905
  • [34] CLINICAL FACTORS PREDISPOSING TO ACHIEVEMENT OF RBC TRANSFUSION INDEPENDENCEIN LENALIDOMIDE-TREATED PATIENTS WITH LOW/INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES) WITHOUT DEL(5q) IN MDS-005 STUDY
    Santini, V.
    Li, J. Shiansong
    Swern, A. S.
    Almeida, A.
    Giagounidis, A.
    Fu, T.
    Sanna, A.
    Hoenekopp, A.
    Beach, C. L.
    Skikne, B.
    Fenaux, P.
    HAEMATOLOGICA, 2015, 100 : 3 - 4
  • [35] MDS-005 STUDY: EFFECT OF BASELINE ENDOGENOUS ERYTHROPOIETIN ON RBC TRANSFUSION INDEPENDENCE IN LENALIDOMIDE-TREATED PATIENTS WITH LOW OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES WITHOUT DEL(5Q)
    Santini, V.
    Li, J. S.
    Swern, A. S.
    Almeida, A.
    Giagounidis, A.
    Fu, T.
    Hoenekopp, A.
    Beach, C.
    Skikne, B.
    Fenaux, P.
    HAEMATOLOGICA, 2015, 100 : 69 - 69
  • [36] THE IPSS-R HAS PROGNOSTIC IMPACT IN UNTREATED PATIENTS WITH MDS DEL(5Q)
    Schemenau, J.
    Lauseker, M.
    Hildebrandt, B.
    Fenaux, P.
    Pfeilstoecker, M.
    Valent, P.
    Platzbecker, U.
    Kuendgen, A.
    Bug, G.
    Haas, R.
    Germing, U.
    LEUKEMIA RESEARCH, 2015, 39 : S157 - S157
  • [37] Correlation between occurrence of cytopeniasand response to lenalidomide therapy in del 5q MDS patients
    Sekeres, A.
    Maciejewski, J. P.
    Giagounidis, A.
    Wride, K.
    Knight, R.
    List, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 83 - 84
  • [38] The IPSS-R has prognostic impact in untreated patients with MDS del(5q)
    Kaivers, J.
    Lauseker, M.
    Hildebrandt, B.
    Fenaux, P.
    Pfeilstoecker, M.
    Valent, P.
    Platzbecker, U.
    Latagliata, R.
    Oliva, E. N.
    Xicoy, B.
    Goetze, K.
    Ganster, C.
    Haase, D.
    Bug, G.
    Kuendgen, A.
    Gattermann, N.
    Haas, R.
    Germing, U.
    LEUKEMIA RESEARCH, 2018, 72 : 27 - 33
  • [39] Frequency and Clinical Impact of Cytogenetic Clonal Evolution in Myelodysplastic Syndromes (MDS) with Isolated Del(5q)
    Zemanova, Zuzana
    Michalova, Kyra
    Brezinova, Jana
    Svobodova, Karla
    Lhotska, Halka
    Sarova, Iveta
    Lizcova, Libuse
    Izakova, Silvia
    Ransdorfova, Sarka
    Pavlistova, Lenka
    Berkova, Adela
    Skipalova, Karolina
    Belickova, Monika
    Siskova, Magda
    Neuwirtova, Radana
    Cermak, Jaroslav
    Stopka, Tomas
    Jonasova, Anna
    BLOOD, 2016, 128 (22)
  • [40] CLONAL EVOLUTION OF HEMATOPOIETIC STEM CELL UNDER TREATMENT BY LENALIDOMIDE IN NON DEL(5Q) MDS
    Chesnais, V.
    Renneville, A.
    Toma, A.
    Passet, M.
    Gauthier, A.
    Delaunay, J.
    Rose, C.
    Stamatoullas, A.
    Beyne-Rauzy, O.
    Fenaux, P.
    Dreyfus, F.
    Preudhomme, C.
    Fontenay, M.
    Kosmider, O.
    LEUKEMIA RESEARCH, 2015, 39 : S74 - S75
12345